Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Fatigue Outcomes of Copaxone Users
NCT00267319Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2003
- Primary completion
- Oct 2006
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Primary endpoint: Fatigue Impact Scale at month 12. Started Jun 2003; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00267319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267319.